Masimo delivered Q3 results that mostly aligned with guidance, yet it faces challenges in its non-healthcare segment.

Executives said the patient monitoring company’s consumer business will likely become a discontinued operation if it is not ...

Masimo (Nasdaq:MASI) shares ticked up before hours today on third-quarter results that came in ahead of the consensus ...

Fintel reports that on November 6, 2024, Raymond James upgraded their outlook for Masimo (NasdaqGS:MASI) from Market Perform ...

Masimo Corp. ( (MASI) ) has released its Q3 earnings. Here is a breakdown of the information Masimo Corp. presented to its investors. Masimo ...

Needham analyst Michael Matson maintained a Hold rating on Masimo (MASI – Research Report) today. The company’s shares closed ...

Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and Masimo's claims are rejected in court. Apple and medical equipment maker ...

The company has discontinued several projects, including noninvasive monitoring of cancer, bilirubin, and diabetes, due to lack of expected progress. Masimo Corp (NASDAQ:MASI) is experiencing ...

Masimo, SET, Signal Extraction Technology, Improving Patient Outcome and Reducing Cost of Care... by Taking Noninvasive Monitoring to New Sites and Applications, rainbow, SpHb, SpOC, SpCO ...

Masimo MASI is set to give its latest quarterly ... and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices ...

Masimo (NASDAQ:MASI ... and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products.

Ladies and gentlemen, good afternoon, and welcome to Masimo's Third Quarter 2024 Earnings ... It's just as we think about the remote monitoring, especially of illicit users, those types of things ...